Altimmune, Inc. 3G0.F Stock
Altimmune, Inc. Price Chart
Altimmune, Inc. 3G0.F Financial and Trading Overview
| Altimmune, Inc. stock price | 6.82 EUR |
| Previous Close | 3.66 EUR |
| Open | 3.67 EUR |
| Bid | 3.68 EUR x 440000 |
| Ask | 3.83 EUR x 420000 |
| Day's Range | 3.67 - 3.67 EUR |
| 52 Week Range | 3.55 - 23.21 EUR |
| Volume | 120 EUR |
| Avg. Volume | 163 EUR |
| Market Cap | 182.06M EUR |
| Beta (5Y Monthly) | -0.065492 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | January 20, 2017 |
| 1y Target Est | 30.86 EUR |
3G0.F Valuation Measures
| Enterprise Value | 23.93M EUR |
| Trailing P/E | N/A |
| Forward P/E | -2.050838 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | -2304.5889 |
| Price/Book (mrq) | 1.078754 |
| Enterprise Value/Revenue | -302.876 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Altimmune, Inc. Stock Price History
| Beta (5Y Monthly) | -0.065492 |
| 52-Week Change | -44.33% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 23.21 EUR |
| 52 Week Low | 3.55 EUR |
| 50-Day Moving Average | 4.25 EUR |
| 200-Day Moving Average | 10.2 EUR |
3G0.F Share Statistics
| Avg. Volume (3 month) | 163 EUR |
| Avg. Daily Volume (10-Days) | 2 EUR |
| Shares Outstanding | 49.29M |
| Float | 42.61M |
| Short Ratio | N/A |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 92.84% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 111562.02% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.050% |
| Return on Equity (ttm) | -48.41% |
Income Statement
| Revenue (ttm) | -79000 EUR |
| Revenue Per Share (ttm) | -0.002 EUR |
| Quarterly Revenue Growth (yoy) | -34.39% |
| Gross Profit (ttm) | -70520000 EUR |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -85357000 EUR |
| Diluted EPS (ttm) | -1.64 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 165.73M EUR |
| Total Cash Per Share (mrq) | 3.36 EUR |
| Total Debt (mrq) | 1.02M EUR |
| Total Debt/Equity (mrq) | 0.61 EUR |
| Current Ratio (mrq) | 11.579 |
| Book Value Per Share (mrq) | 3.403 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -68467000 EUR |
| Levered Free Cash Flow (ttm) | -47639752 EUR |
Profile of Altimmune, Inc.
| Country | Germany |
| State | MD |
| City | Gaithersburg |
| Address | 910 Clopper Road |
| ZIP | 20878 |
| Phone | 240 654 1450 |
| Website | https://altimmune.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 52 |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Q&A For Altimmune, Inc. Stock
What is a current 3G0.F stock price?
Altimmune, Inc. 3G0.F stock price today per share is 6.82 EUR.
How to purchase Altimmune, Inc. stock?
You can buy 3G0.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Altimmune, Inc.?
The stock symbol or ticker of Altimmune, Inc. is 3G0.F.
Which industry does the Altimmune, Inc. company belong to?
The Altimmune, Inc. industry is Biotechnology.
How many shares does Altimmune, Inc. have in circulation?
The max supply of Altimmune, Inc. shares is 71.21M.
What is Altimmune, Inc. Price to Earnings Ratio (PE Ratio)?
Altimmune, Inc. PE Ratio is now.
What was Altimmune, Inc. earnings per share over the trailing 12 months (TTM)?
Altimmune, Inc. EPS is -1.5 EUR over the trailing 12 months.
Which sector does the Altimmune, Inc. company belong to?
The Altimmune, Inc. sector is Healthcare.